Literature DB >> 9565807

Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment.

P Scalfaro1, J J Chesaux, P A Buchwalder, J Biollaz, J L Micheli.   

Abstract

Zidovudine (ZDV) treatment during pregnancy, delivery and the postnatal period is effective in reducing the maternal-infant transmission of the human immunodeficiency virus. Reported adverse effects in the neonate during this longterm treatment are bone marrow suppression and elevation in aspartate aminotransferase activity. We report a case of severe ZDV-associated lactic acidosis in a neonate, which resolved rapidly following discontinuation of ZDV. The mechanisms leading to this side effect are poorly understood.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9565807     DOI： 10.1007/s001340050558

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN： 0342-4642            Impact factor:   17.440


  8 in total

1.  Lactic acidosis complicating the acquired immunodeficiency syndrome.

Authors:  G Chattha; A I Arieff; C Cummings; L M Tierney
Journal:  Ann Intern Med       Date:  1993-01-01       Impact factor: 25.391

2.  [Lactic acidosis in HIV infected patients].

Authors:  C Maslo; C Jacomet; J J Jupas; M G Lebrette; W Rozenbaum
Journal:  Presse Med       Date:  1994-04-16       Impact factor: 1.228

3.  Chronic lactic acidosis in a patient with acquired immunodeficiency syndrome and mitochondrial myopathy: biochemical studies.

Authors:  R Gopinath; M Hutcheon; S Cheema-Dhadli; M Halperin
Journal:  J Am Soc Nephrol       Date:  1992-12       Impact factor: 10.121

4.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

5.  Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.

Authors:  C H Chen; M Vazquez-Padua; Y C Cheng
Journal:  Mol Pharmacol       Date:  1991-05       Impact factor: 4.436

6.  Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus.

Authors:  F D Boucher; J F Modlin; S Weller; A Ruff; M Mirochnick; S Pelton; C Wilfert; R McKinney; M J Crain; M M Elkins
Journal:  J Pediatr       Date:  1993-01       Impact factor: 4.406

7.  Trimethoprim, alone or in combination with sulphamethoxazole, decreases the renal excretion of zidovudine and its glucuronide.

Authors:  J Y Chatton; A Munafo; J P Chave; F Steinhäuslin; F Roch-Ramel; M P Glauser; J Biollaz
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335

8.  Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn.

Authors:  J F Tolsa; J Cotting; N Sekarski; M Payot; J L Micheli; A Calame
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-05       Impact factor: 5.747
  8 in total
  9 in total

Review 1.  Tolerabilities of antiretrovirals in paediatric HIV infection.

Authors:  Daniel Avi Lemberg; Pamela Palasanthiran; Michele Goode; John B Ziegler
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.

Authors:  Wycliffe O Opii; Rukhsana Sultana; Hafiz Mohmmad Abdul; Mubeen Ahmad Ansari; Avindra Nath; D Allan Butterfield
Journal:  Exp Neurol       Date:  2006-10-25       Impact factor: 5.330

3.  Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications.

Authors:  Marilyn J Crain; Paige L Williams; Ray Griner; Katherine Tassiopoulos; Jennifer S Read; Lynne M Mofenson; Kenneth C Rich
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

Review 4.  Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?

Authors:  G Moyle
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

5.  Serum lactate levels in infants exposed peripartum to antiretroviral agents to prevent mother-to-child transmission of HIV: Agence Nationale de Recherches Sur le SIDA et les Hépatites Virales 1209 study, Abidjan, Ivory Coast.

Authors:  Didier Koumavi Ekouevi; Ramata Touré; Renaud Becquet; Ida Viho; Charlotte Sakarovitch; François Rouet; Besigin Towne-Gold; Patricia Fassinou; Valériane Leroy; Stéphane Blanche; François Dabis
Journal:  Pediatrics       Date:  2006-09-01       Impact factor: 7.124

6.  The chemical bases of the various AIDS epidemics: recreational drugs, anti-viral chemotherapy and malnutrition.

Authors:  Peter Duesberg; Claus Koehnlein; David Rasnick
Journal:  J Biosci       Date:  2003-06       Impact factor: 1.826

Review 7.  Advances and failures in preventing perinatal human immunodeficiency virus infection.

Authors:  Ann M Buchanan; Coleen K Cunningham
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

8.  German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

Authors:  Bernd Buchholz; Matthias Beichert; Ulrich Marcus; Thomas Grubert; Andrea Gingelmaier; Annette Haberl; Brigitte Schmied
Journal:  Eur J Med Res       Date:  2009-11-03       Impact factor: 2.175

9.  Mitochondrial toxicity and caspase activation in HIV pregnant women.

Authors:  Sandra Hernandez; Constanza Moren; Marc Catalán-García; Marta Lopez; Mariona Guitart-Mampel; Oriol Coll; Laura Garcia; Jose Milisenda; Angela Justamante; Josep Maria Gatell; Francesc Cardellach; Eduard Gratacos; Òscar Miro; Gloria Garrabou
Journal:  J Cell Mol Med       Date:  2016-08-30       Impact factor: 5.310
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.